Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Wolf J, et al. Among authors: waldron lynch m. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. N Engl J Med. 2020. PMID: 32877583 Clinical Trial.
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S, Cortés J. Schneeweiss A, et al. Among authors: waldron lynch m. Eur J Cancer. 2018 Jan;89:27-35. doi: 10.1016/j.ejca.2017.10.021. Epub 2017 Dec 8. Eur J Cancer. 2018. PMID: 29223479 Clinical Trial.
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group. Swain SM, et al. Among authors: waldron lynch m. Ann Oncol. 2018 Mar 1;29(3):646-653. doi: 10.1093/annonc/mdx773. Ann Oncol. 2018. PMID: 29253081 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36164038
[No title available]
[No authors listed] [No authors listed] PMID: 36164037
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwana N, Waldron-Lynch M, Davis KL, Giovannini M, Awad MM. Wolf J, et al. Among authors: waldron lynch m. Clin Lung Cancer. 2023 Nov;24(7):641-650.e2. doi: 10.1016/j.cllc.2023.08.011. Epub 2023 Aug 13. Clin Lung Cancer. 2023. PMID: 37741716
11 results